Axial Therapeutics to Present at Upcoming Conferences WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological...

Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease –Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of disease in PD– –IND-enabling...

Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD) -- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on...

Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics – Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...

Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments - Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...